BLM and glioblastoma: This study evaluated the response of RECQL4-depleted cells to chemotherapeutic agents, including the combination of TMZ and OLA, as well as WP744, a doxorubicin derivative, aiming to elucidate the specific roles of the RECQL4 and BLM helicases in the therapeutic response of GBM cells.